MEDC.jk: Waiting for proof – CFROA 5%, Market 1%
June 30, 2025 – Based on March Cashflows
Cashflow return on assets (CFROA) is steady at 5%, but the latest quarter brought only a small positive cashflow — and more debt.
Shares are down –6% YoY, but have climbed +12% year-to-date, still leaving the market value equivalent at just 1%, reflecting continued scepticism after years of negative cashflow.
Leverage remains high with liabilities minus cash over assets at 63%.
Rank: #106 — just outside the Top 100.
⸻
Data ⛽️
• CFROA: 5% (unchanged)
• Market Value Equivalent: 1%
• Share Price: –6% YoY, +12% YTD
• Leverage: 63%
• Rank: #106
⸻
🔍 Still waiting for consistent cashflow to support the share recovery. Keep watching.
⸻
For full access to our cashflow rankings, morning meetings, and model portfolio, visit:
👉 sharpfokus.com/subscribe
For informational purposes only, not investment advice.
June 30, 2025 – Based on March Cashflows
Cashflow return on assets (CFROA) is steady at 5%, but the latest quarter brought only a small positive cashflow — and more debt.
Shares are down –6% YoY, but have climbed +12% year-to-date, still leaving the market value equivalent at just 1%, reflecting continued scepticism after years of negative cashflow.
Leverage remains high with liabilities minus cash over assets at 63%.
Rank: #106 — just outside the Top 100.
⸻
Data ⛽️
• CFROA: 5% (unchanged)
• Market Value Equivalent: 1%
• Share Price: –6% YoY, +12% YTD
• Leverage: 63%
• Rank: #106
⸻
🔍 Still waiting for consistent cashflow to support the share recovery. Keep watching.
⸻
For full access to our cashflow rankings, morning meetings, and model portfolio, visit:
👉 sharpfokus.com/subscribe
For informational purposes only, not investment advice.